Maruho Report 2023

22/60

• Manufacturing and marketing approval: 9 cases*• Strengthened late phase pipeline• Established a system for incubating candidates for in-licensing with external organizations* Zebiax Oily Cream, Comclo Shampoo,† Rozex Gel,† Rapifort Wipes, Mitchga Syringes, DermaQuick HSV, Amenalief,† • Increased production and strengthened stable supply structure through coordination • Improved capabilities by meeting demand for new products and completed renovation • Implemented risk-hedging measures including diversifying API procurement• Established a system for digital and real-time information delivery in response to • Established the function and structure for information provision as a leader in the area • Formulated the Asia Dermatology Hub Concept for business to promote the growth of • Launched sales of Farom in China, which was registered on the national medical • Acquired new projects and made progress in new domains• Provided innovative therapeutic approach in the pincer nails business• Established the business base for cosmetics and quasi-pharmaceutical products with • Promoted skin-care guidance to patients during treatment through the iniks skin-care brand• Formulated a new Corporate Philosophy and announced it internally and externally• Implemented measures related to career autonomy p. 33 “Social—Working with employees”• Published Maruho Report as a business activity report for external dialogue and fostering trust21Review of business activitiesReview of management basePillars of strategyMaruho Report 2023Create products for the global market (Manufacturing)Products and manufacturing plants that are continuously chosen (Production)High-quality information provision reflecting the voices of patients (Providing information)Establish processes for providing product value in the global market (Global presence)Expand business areas utilizing the strengths of the Maruho Group (Activities other than prescription drugs for skin diseases)Management base to support further growth (Management base)Main initiatives and resultsp. 1 “Corporate Philosophy and Meaning of Existence”In the fiscal year ended September 30, 2023, Maruho Group achieved solid results under the Fourth Medium-Term Plan. We formulated the Fifth Medium-Term Plan under the corporate mission of “More smiles, brighter life for you.” with the aim of establishing a growth trend.2. Value Creation Prospects Overview of the Medium-Term PlanFourth Medium-Term Plan (October 2020 to September 2023)Renail Gel, BEPIO Lotion († additional indication)between our four plantsof the filling and packaging building at Hikone Plantpatients’ voicesof skin diseaseour business in Asia insurance reimbursement listthe Carté HD line of Kose Maruho Pharma Co., Ltd. Sustainable growth and progressive challenge